Effect of Acorus calamus L. Polysaccharide on CD274 and CD326 Expression by Lewis Lung Carcinoma Cells in Mice


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

Tumor cells can maintain their growth via immunosuppression and escape from host antitumor immunity by controlling the PD-1/PD-L1 system. Expression of PD-L1 (CD274) is an inhibitory signal for T cells, while the increase in CD326 expression in the tumor tissue correlates with metastasis development. The experimental preparation on the basis of α(1,2)-L-rhamno-α(1,4)-D-galactopyranosyluronan from Acorus calamus L. produces an antitumor effect: it reduces tumor node size and the number and area of metastases after transplantation of Lewis lung carcinoma. Using flow cytometry, we demonstrated a decrease in the population of tumor cells expressing surface CD274 (PD-L1) and CD326 antigens after 20-day course of α(1,2)-L-rhamno-α(1,4)-D-galactopyranosyluronan.

Sobre autores

K. Lopatina

Laboratory of Oncopharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center; Laboratory of Phytochemistry of Siberian Botanical Garden of National Research Tomsk State University

Autor responsável pela correspondência
Email: k.lopatina@pharmso.ru
Rússia, Tomsk; Tomsk

E. Safonova

Laboratory of Oncopharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: k.lopatina@pharmso.ru
Rússia, Tomsk

K. Nevskaya

Department of Pharmaceutical Analysis, Centre for Introduction of Technologies, Siberian State Medical University, Ministry of Health of the Russian Federation

Email: k.lopatina@pharmso.ru
Rússia, Tomsk

M. Stakheeva

Laboratory of Molecular Oncology and Immunology, Research Institute of Oncology, Tomsk National Research Medical Center

Email: k.lopatina@pharmso.ru
Rússia, Tomsk

A. Gur’ev

Department of Pharmaceutical Analysis, Centre for Introduction of Technologies, Siberian State Medical University, Ministry of Health of the Russian Federation

Email: k.lopatina@pharmso.ru
Rússia, Tomsk

E. Zueva

Laboratory of Oncopharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: k.lopatina@pharmso.ru
Rússia, Tomsk

T. Razina

Laboratory of Oncopharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: k.lopatina@pharmso.ru
Rússia, Tomsk

E. Amosova

Laboratory of Oncopharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: k.lopatina@pharmso.ru
Rússia, Tomsk

S. Krylov

Laboratory of Oncopharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: k.lopatina@pharmso.ru
Rússia, Tomsk

M. Belousov

Department of Pharmaceutical Analysis, Centre for Introduction of Technologies, Siberian State Medical University, Ministry of Health of the Russian Federation

Email: k.lopatina@pharmso.ru
Rússia, Tomsk


Declaração de direitos autorais © Springer Science+Business Media, LLC, part of Springer Nature, 2017

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies